- Home
- AU vs ROIV Comparison
AU vs ROIV Comparison
Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | ROIV |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 14.1B |
| IPO Year | 1972 | N/A |
Fundamental Metrics
Financial Performance| Metric | AU | ROIV |
|---|---|---|
| Price | $86.88 | $21.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $82.67 | $24.31 |
| AVG Volume (30 Days) | 2.5M | ★ 8.2M |
| Earning Date | 02-18-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 237.48 | N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $8,575,000,000.00 | $20,329,000.00 |
| Revenue This Year | $71.69 | N/A |
| Revenue Next Year | $14.39 | $741.42 |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | ★ 61.82 | N/A |
| 52 Week Low | $22.45 | $8.73 |
| 52 Week High | $91.65 | $23.47 |
Technical Indicators
Market Signals| Indicator | AU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 51.86 |
| Support Level | $83.79 | $21.60 |
| Resistance Level | $91.65 | $22.72 |
| Average True Range (ATR) | 3.00 | 0.81 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 59.07 | 43.03 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.